Post Robert M, Rybakowski Janusz K
Bipolar Collaborative Network, Chevy Chase, MD 20815, USA.
Department of Adult Psychiatry, Poznan University of Medical Sciences, 61-701 Poznań, Poland.
Pharmaceuticals (Basel). 2024 Sep 17;17(9):1223. doi: 10.3390/ph17091223.
Lithium is the superior first-line treatment for bipolar disorder (BD). Yet the percentage of patients receiving lithium is abysmally low, especially in the US. Since psychiatrists have failed to place lithium in its appropriate role, we make the case that patients with BD themselves need to be better educated about the unique characteristics and pre-eminence of the drug so that it can be used more often and appropriately. Lithium has a highly unfavorable popular reputation among would-be patients and many psychiatrists. Thus, a direct appeal to patients with BD appears appropriate to try to remediate this situation. The unique assets of lithium are underappreciated or not well known. Conversely, the side effects profile of lithium are overestimated. Here, we make the case that lithium's image needs to be revised not only with better and more accurate information but also with a wholesale renaming and rebranding of the drug. We will not only outline the unique qualities and new information about the side effects of the drug but attempt to change some of the terminology conventionally used to refer to lithium so that its use may be appropriately applied earlier and at an increased frequency for patients with BD.
锂盐是双相情感障碍(BD)的首选一线治疗药物。然而,接受锂盐治疗的患者比例极低,尤其是在美国。由于精神科医生未能让锂盐发挥其应有的作用,我们认为双相情感障碍患者自身需要更好地了解这种药物的独特特性和卓越性,以便能更频繁、恰当地使用它。锂盐在潜在患者和许多精神科医生中口碑极差。因此,直接向双相情感障碍患者呼吁似乎是改善这种情况的合适做法。锂盐的独特优势未得到充分认识或广为人知。相反,锂盐的副作用却被高估了。在此,我们认为不仅需要用更好、更准确的信息,还需要对该药物进行全面的重新命名和重新定位,来修正锂盐的形象。我们不仅将概述该药物的独特性质和关于其副作用的新信息,还将尝试改变一些传统上用于指代锂盐的术语,以便能更早且更频繁地为双相情感障碍患者恰当地使用它。